News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Prasco Laboratories Launches Authorized Generic of Lysteda® (tranexamic acid) Tablets


1/7/2013 1:12:05 PM

CINCINNATI, OH; 1/07/13 — Prasco Laboratories announced today it began shipping the Authorized Generic of Ferring’s LYSTEDA® (tranexamic acid) Tablets in 650 mg strength in the U.S. under the Prasco label. Tranexamic acid tablets are AB-rated and substitutable for the brand LYSTEDA Tablets.

“We are pleased to welcome Ferring Pharmaceuticals into Prasco’s family of brand partners with the introduction of the Authorized Generic of LYSTEDA Tablets,” stated Prasco Chief Executive Officer, Chris Arington. “With the choice of tranexamic acid tablets, customers benefit from the same consistent supply and quality of the brand they are accustomed to,” Arington continued. “Ultimately, the patient benefits through continuity of therapy by remaining on the identical brand product at generic savings.”

As the leader in the Authorized Generics business, Prasco has now brought over 40 Authorized Generics to market, more than any other company in the United States. Leading companies work with Prasco to bring their branded products to the generic marketplace as Authorized Generics, which offer alternatives to physicians, patients and pharmacists.

Tranexamic Acid Tablets 650 mg is an antifibrinolytic drug indicated for the treatment of cyclic heavy menstrual bleeding. The most common adverse reactions in clinical trials (=5%, and more frequent in LYSTEDA subjects compared to placebo subjects) were: headache, sinus and nasal symptoms, back pain, abdominal pain, musculoskeletal pain, joint pain, muscle cramps, migraine, anemia, and fatigue. LYSTEDA is contraindicated in women with active thromboembolic disease or a history or intrinsic risk of thrombosis or thromboembolism, including retinal vein or artery occlusion; or known hypersensitivity to tranexamic acid. The risk of thrombotic and thromboembolic events may increase further when hormonal contraceptives are administered with LYSTEDA, especially in women who are obese or smoke cigarettes. Women using hormonal contraception should use LYSTEDA only if there is a strong medical need and the benefit of treatment will outweigh the potential increased risk of a thrombotic event. Do not use LYSTEDA in women who are taking more than the approved dose of a hormonal contraceptive. For additional information, please click here to see the Full Prescribing Information.

LYSTEDA is a registered trademark of Ferring B.V.

About Ferring Pharmaceuticals Inc. – Ferring Pharmaceuticals Inc. is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology and endocrinology. Ferring has operating subsidiaries in over 45 countries. To learn more about Ferring or our products please visit www.ferring.com.

About Prasco Laboratories – Prasco, the Authorized Generic company, is the privately held healthcare company located in Mason, Ohio. The leader in Authorized Generics, Prasco has more Authorized Generic partnerships than any other company. Established brand companies rely on Prasco to bring their brand products to the generic marketplace as Authorized Generics, which offers alternatives to consumers and pharmacists. For more information, visit www.prasco.com.

CONTACT: Kimberly A. Carroll

Advisor to the Chairman,

Corporate Marketing & Communications

k.carroll@prasco.com

513.204.1277

513.550.1473 C


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES